Patients were eligible if they had advanced NSCLC involving mutation(s), were clinically resistant to EGFR TKIs (gefitinib, erlotinib, icotinib, or afatinib), and were undergoing re-biopsy for genotyping as part of their routine clinical care
Patients were eligible if they had advanced NSCLC involving mutation(s), were clinically resistant to EGFR TKIs (gefitinib, erlotinib, icotinib, or afatinib), and were undergoing re-biopsy… Read More »Patients were eligible if they had advanced NSCLC involving mutation(s), were clinically resistant to EGFR TKIs (gefitinib, erlotinib, icotinib, or afatinib), and were undergoing re-biopsy for genotyping as part of their routine clinical care